

94 53. A method of treating a mammal having prostate cancer, comprising administering to the mammal Apo-2 ligand polypeptide in an amount effective to induce cell death in the mammal's cancer cells.

54. The method of claim 53 wherein radiation therapy or chemotherapy is further administered to the mammal.

55. The method of claim 54 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered concurrently.

56. The method of claim 54 wherein the chemotherapy is selected from the group consisting of Doxorubicin, 5-Fluorouracil, Cytosine arabinoside, Cyclophosphamide, Thiotepe, Busulfan, Cytosine, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, and Carboplatin.

57. The method of claim 53 wherein the Apo-2 ligand polypeptide is selected from the group:

- (a) a polypeptide comprising amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);
- (b) a polypeptide comprising a fragment or variant of (a); and
- (c) a polypeptide consisting of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

58. The method of claim 53 wherein the Apo-2 ligand polypeptide is linked to a nonproteinaceous polymer selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene. --

#### REMARKS

As shown above, certain amendments to the specification have been requested. In particular, the specification has been amended to reflect the current address of the ATCC depository. Further, Applicant is submitting herewith a paper copy of a substitute Sequence Listing which includes the sequences disclosed in Figure 1B. The

specification has been amended to recite the appropriate sequence identifiers in the specification. It is believed that the substitute Sequence Listing brings the application into compliance with the rules provided in Sections 1.821-1.825.

Claims 1-23 and 26-29, as originally filed in the parent application, have been canceled without prejudice. Claim 24 has been amended, and claims 30-58 added. The amendments to claim 24 and added claims 30-58 are fully supported by the specification, and accordingly are not believed to introduce new matter into the application.

Respectfully submitted,  
GENENTECH, INC.

Date: December 13, 1999

By: *Diane L. Marschang*  
Diane L. Marschang  
Reg. No. 35,600

1 DNA Way  
So. San Francisco, CA 94080-4990  
Phone: (650) 225-5416  
Fax: (650) 952-9881